SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McGuire, D.
Right arrow Articles by Marder, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, D.
Right arrow Articles by Marder, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pharmacological frontiers in the treatment of AIDS dementia

Dawn McGuire

Department of Neurology, UCSF Medical Center, San Francisco; 643 Bair Island Road Suite 210 Redwood City, CA USA; dmcguire{at}csfluids.com

Karen Marder

Columbia Presbyterian Medical Centre, New York, NY, USA

Even in the era of highly active antiretroviral therapy, AIDS dementia remains an important and devastating complication of human immunodeficiency virus (HIV-1) infection. Based on the 1997 AIDS case rate of 56 per 100 000 population in the USA, a reasonable estimated incidence of AIDS dementia is 3–8 per 100 000, similar to that of multiple sclerosis. The pharmacology of AIDS dementia has been dominated by antiretroviral therapies, the best studied of which is azidothymidine. New and specific therapies are needed to treat and prevent brain injury in the setting of HIV infection. Rational therapy has been limited by the absence of large, adequate and well-controlled clinical trials using neuroprotective agents or those with disease-modifying potential, as well as by an incomplete understanding of the pathophysiology of AIDS dementia. In this review, a summary of evidence-based hypotheses of HIV-associated brain injury is followed by information on current nonantiretroviral therapeutic trials and their scientific rationale.

Key Words: AIDS clinical trials • AIDS dementia complex • drug therapy • HIV encephalitis • neuroprotective agents

Journal of Psychopharmacology, Vol. 14, No. 3, 251-257 (2000)
DOI: 10.1177/026988110001400310
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
S. Saddichha and V. Pandey
Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies
American Journal of Alzheimer's Disease and Other Dementias, May 1, 2008; 23(2): 150 - 161.
[Abstract] [PDF]

Home page
 JAMAHome page
G. J. Treisman, A. F. Angelino, and H. E. Hutton
Psychiatric Issues in the Management of Patients With HIV Infection
JAMA, December 12, 2001; 286(22): 2857 - 2864.
[Abstract] [Full Text] [PDF]


Advertisement